Abstract 44P
Background
In metastatic NSCLC TPS PDL1
Methods
We retrospectively analyzed 363 metastatic NSCLC patients with programmed cell-death ligand (PD-L1) TPS
Results
At a median follow-up of 12 months, no statistically significant differences were revealed in median OS between patients treated with chemotherapy plus Nivolumab and Ipilimumab or with chemotherapy plus pembrolizumab. A clinically but not statistically significant improvement in median OS has emerged in PD-L1 positive vs negative patients, regardless chemo-immunotherapy regimen. Bone metastasis were associated with a worse prognosis vs no bone metastasis patients (median OS 6.4 vs 13.2 months, log rank test p value=0.0002). Liver metastasis also resulted in a bad prognosis with a median OS of 4.9 months vs 11.4 months of no liver metastasis patients. (p value=0.011). NLR from the pretreatment complete blood counts reflected a poor treatment benefits if equal or higher than 3.8. Finally, presence of pathogenetic KRAS gene variants did not have a negative impact on prognosis.
Conclusions
High NLR, Bone and Liver metastasis are associated to significantly shorter overall survival in previously untreated patients with NSCLC with lower or negative expression of PD-L1 and treated in first-line with chemo-immunotherapy.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.